



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/22 // (A61K 38/22, 31:57)	A1	(11) International Publication Number: WO 95/11696 (43) International Publication Date: 4 May 1995 (04.05.95)
(21) International Application Number: PCT/US94/12106 (22) International Filing Date: 21 October 1994 (21.10.94) (30) Priority Data: 08/141,013 26 October 1993 (26.10.93) US (71) Applicants: ALPHA 1 BIOMEDICALS, INC. [US/US]; Two Democracy Center, Suite 1200, 6903 Rockledge Drive, Bethesda, MD 20817 (US). THE BOARD OF GOVERNORS OF WAYNE STATE UNIVERSITY [US/US]; Wayne State University, Detroit, MI 48202 (US). (72) Inventors: CHRETIEN, Paul, B.; 10201 Grosvenor Place, Rockville, MD 20852 (US). MUTCHNICK, Milton, G.; 6051 Charles Drive, West Bloomfield, MI 48322 (US). (74) Agents: REPPER, George, R. et al.; Rothwell, Figg, Ernst & Kurz, 555 13th Street, N.W. #701 East, Washington, DC 20004 (US).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>With amended claims.</i>
(54) Title: COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE HEPATITIS CONTAINING THYMOSIN ALPHA I AND A CORTICOSTEROID (57) Abstract A method and composition for treating autoimmune hepatitis in a patient utilizes an immunomodulatory amount of Tα₁ and an anti-inflammatory amount of a corticosteroid. Acute toxicity studies of Tα₁ in mice, rats, marmosets and dogs demonstrated no adverse effects at doses up to 0.25 mg/kg/day for 14 days. Chronic toxicity studies of Tα₁ in mice and marmosets demonstrated no adverse effects at doses up to 1 mg/kg/day for 26 weeks.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

**Composition for the treatment of autoimmune hepatitis
containing thymosin alpha i and a corticosteroid.**

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

5 The present invention relates to a method and composition for treating autoimmune hepatitis in mammals.

DESCRIPTION OF BACKGROUND ART

10 The term "autoimmune disorder" is an umbrella-like term which is used to refer to a large group of unrelated illnesses with unknown causes, but associated with abnormalities in immunoregulation.

15 Hepatitis is an inflammatory process in the liver which can be caused by a variety of aetiologies, including viruses and drugs.

20 When a patient is suffering from a chronic hepatitis, but the cause of the disease is not known (i.e., following exclusion of other causes), and is associated with abnormalities in immunoregulation, the patient is said to have "autoimmune hepatitis". Untreated, autoimmune hepatitis is progressive, and can result in liver failure and death.

25 One current treatment for autoimmune hepatitis requires prolonged administration of corticosteroids such as prednisone and prednisolone. While corticosteroid therapy has been shown to extend life, improve biochemical abnormalities and enhance quality of life in many patients, the beneficial effects of

corticosteroids are offset by the often serious complications and side effects associated with the prolonged treatment therewith.

While there have been several proposals for treating autoimmune hepatitis with extracts of calf thymus (e.g., Hegarty et al., Gut 25:279-283 (1984), and O'Brien et al., Int. J. Immunopharmac. 10:651-658 (1988)), none have heretofore been shown to be successful.

There remains a need in the art for new and improved methods and compositions for treating autoimmune hepatitis.

SUMMARY OF THE INVENTION

In accordance with the present invention, a method of treating autoimmune hepatitis in a patient comprises administering to a patient in need of such treatment a drug regimen comprising an immunomodulatory amount of Thymosin α_1 and an anti-inflammatory amount of a corticosteroid.

The invention further includes a pharmaceutical composition comprising separate pharmaceutical dosage units of an immunomodulatory amount of Thymosin α_1 and an anti-inflammatory amount of a corticosteroid.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

Autoimmune hepatitis is referred to as such because it is a chronic hepatitis of unknown aetiology, when other causes of hepatitis have been excluded. Autoimmune hepatitis can further be classified as follows.

Type 1, or "classic" autoimmune hepatitis, is characterized in patients by the presence of antinuclear antibodies (ANA) in approximately 70% of such patients, the presence of anti-smooth muscle (anti-actin) antibodies (SMA) in more than 30% of such

patients, and sensitivity to corticosteroids.

Type 2 autoimmune hepatitis is characterized by the presence of anti-liver-kidney-microsomal antibodies (ANTI-LKM-1), absence of ANA and SMA, and sensitivity to corticosteroids.

Type 3 autoimmune hepatitis patients are characterized by the presence by liver-pancreas antigen antibody (ANTI-LP) or anti-soluble liver antigen antibodies (ANTI-SLA), absence of ANA and ANTI-LKM-1, presence of SMA in 30% of such patients, and sensitivity to corticosteroids.

Type 4 autoimmune hepatitis patients are characterized as cryptogenic (tentative), and are characterized by the absence of ANA, SMA, ANTI-LKM-1, ANTI-SLA and ANTI-LP, and sensitivity to corticosteroids.

It has surprisingly been discovered that Thymosin α_1 and corticosteroids appear to act synergistically in the treatment of autoimmune hepatitis.

As noted above, a method of treating autoimmune hepatitis in a patient in accordance with the present invention, comprises administering to a patient in need of such treatment a drug regimen comprising an immunomodulatory amount of Thymosin α_1 and an anti-inflammatory amount of a corticosteroid. Suitable corticosteroids for use in accordance with the present invention include, but are not limited to, prednisone and prednisolone.

Anti-inflammatory amounts of a corticosteroid for a human adult patient are included within the oral dosage range of about 1 - 100 mg per administration. Preferably, the amount of corticosteroid administered is sufficient to reduce serum transaminase levels of the patient, decrease necroinflammatory activity in the

liver and inhibit progression of liver cirrhosis.

The terms "Thymosin α_1 " and " $T\alpha_1$ " as used herein encompasses not only native (i.e., naturally occurring) $T\alpha_1$ but also synthetic $T\alpha_1$ and recombinant $T\alpha_1$ having the amino acid sequence of native $T\alpha_1$, amino acid sequences substantially similar thereto, or an abbreviated sequence from thereof, and their biologically active analogs (including muteins) having substituted, deleted, elongated, replaced, or otherwise modified sequences which possess bioactivity substantially similar to that of $T\alpha_1$.

Immunomodulatory amounts of Thymosin α_1 for a human adult patient are included within the dosage range of 0.4 - 4 mg per administration by subcutaneous injection. Such amounts can be sufficient to stimulate T-lymphocytes and CD4 cells in autoimmune hepatitis patients.

Without being bound to any particular theory, disturbances in immunoregulation may see expression in the control of autoreactivity in autoimmune hepatitis. The perturbation may reside in subsets of T-cells or reflect the influence of cytokine mediators on antigen-presenting cells, autoreactive T-cells or, on cell surfaces of hepatocytes.

The course of the autoimmune hepatitis and its response to treatment may be followed by clinical examination and laboratory findings. Elevated serum transaminases, including serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) occur in uncontrolled autoimmune hepatitis. A treatment response can be defined as reduction of serum transaminase levels to about two times the upper limit of normal serum transaminase levels. Baseline values for normal serum transaminase levels may vary according

to the assay used, but typically, high normal values are within the range of about 35 - 65 IU/L for ALT or AST. A complete response to treatment can be defined as normalization of these serum enzymes, particularly ALT. Accordingly, progress of treatment can conveniently be followed by measuring serum transaminases levels, for example, on a sequential multiple analyzer.

A preferred embodiment in accordance with the present invention involves administration of a regimen of doses of anti-inflammatory amounts of a corticosteroid, without administration of $T\alpha_1$, so as to reduce transaminase levels of the patient to a target level of less than about two times the upper limit of normal serum transaminase levels, or to normal or near normal levels if possible. After reduction of the patient's transaminase levels to the target levels, the patient's maintenance dose of corticosteroid can be determined. Then, administration of a dose regimen of an immunomodulatory amount of $T\alpha_1$ can be commenced, while continuing corticosteroid administration. During subsequent co-administration of the corticosteroid and $T\alpha_1$, the patient's maintenance dose of corticosteroid may be reduced, while maintaining the serum transaminase levels at or below the target levels.

In particularly preferred embodiments, Thymosin α_1 is administered by subcutaneous injection twice weekly at a dose within the range of about 1 - 4 mg (e.g., about 1.6 mg), and the corticosteroid is administered orally once daily, or on an alternating day regimen, at a dose within the range of about 2-60 mg. However, it is to be understood that separate pharmaceutical dosage units containing Thymosin α_1 and the corticosteroid, respectively, may be formulated in any suitable manner

for administration by any suitable route. Suitable routes of administration may include, but are not limited to, oral, parenteral (including subcutaneous, intramuscular, intravenous and intradermal) and transdermal. Particularly preferred embodiments utilize parenteral and/or oral administration.

In preferred embodiments, $T\alpha_1$ and the corticosteroid are administered as separate pharmaceutical dosage units. The separate dosage units of the present invention include one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients. The carrier(s) are "acceptable" in the sense of being compatible with the other ingredients of the dosage unit formulation and not deleterious to the recipient thereof.

The separate dosage unit formulations may be prepared by any suitable pharmaceutical methods.

Such methods may include the step of separately bringing into association the respective active ingredient ($T\alpha_1$ or the corticosteroid) with its carrier, which may comprise one or more ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the respective active ingredient with liquid carriers or finely divided solid carriers or both. Solid dosage unit formulations also may include the step of shaping the product.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets, containing a predetermined amount of the particular active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a

water-in-oil liquid emulsion, etc.

A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a
5 suitable machine, free-flowing powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound
10 moistened with an inert liquid diluent. Tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein.

Formulations suitable for parenteral
15 administration include aqueous and non-aqueous sterile injection solutions which may optionally contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile
20 suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the
25 addition of the sterile liquid carrier, for example water for injection, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.

30 Suitable dosage units of $T\alpha_1$ and the corticosteroid can be administered to the patient daily, one or more times per day, e.g., two or three times per day, and doses can be administered one or more days per week, e.g., two, three, four, five, six or seven days per
35 week.

The invention is further illustrated by the following examples, which are not intended to be limiting. The examples involve four patients (two women and two men) with Type 1 autoimmune hepatitis.

5 Three of the patients were previously receiving prednisone, and one patient was newly diagnosed and untreated. In each case, $T\alpha_1$ was administered at a dosage level of 1.6 mg by subcutaneous injection, twice weekly. Prednisone was administered orally. Acute

10 toxicity studies of $T\alpha_1$ in mice, rats, marmosets and dogs demonstrated no adverse effects at doses up to 0.25 mg/kg/day for 14 days. Chronic toxicity studies of $T\alpha_1$ in mice and marmosets demonstrated no adverse effects at doses up to 1 mg/kg/day for 26 weeks.

15 Information on safety and use of prednisone is available in Physicians' Desk Reference, 46th Ed., Montvale, NJ, U.S.A., pp. 2332-2334 (1992).

Example 1

20 Patient was a 52 year old white female diagnosed with chronic autoimmune hepatitis at age 45. Patient presented with elevated transaminases, fatigue and lower extremity edema. At that time her transaminases were 6 to 10 times the upper limit of normal. A biopsy showed chronic active cirrhosis and serologies were

25 positive for ANA and SMA.

Patient was started on 40 mg of prednisone daily. A slow taper was undertaken. Patient's transaminases remained near normal at a dose of 12.5 mg per day. However, with subsequent attempts to lower the

30 prednisone dose further, patient's transaminases would flare. At this dose she had some problems with fluid retention and dyspepsia.

She was offered 1.6 mg Thymosin α_1 injections twice weekly. She agreed to this trial and injections were then started. The prednisone was eventually decreased to 2.5 mg every other day. At this low dose, she did
5 have a transient flare in her transaminases and the prednisone was temporarily increased back to 20. Subsequently, on a continued dose of 5 mg a day, patient did well. Her transaminases remained near normal and she experienced no further problems with
10 fluid retention. She was able to discontinue her diuretics.

After maintaining the transaminases with twice weekly thymosin injections and prednisone at 5 mg a day, we elected to discontinue thymosin and observe the
15 results. She experienced an increase in her transaminases and the thymosin was thus subsequently restarted, along with prednisone at 10 mg daily, with normalization once again of her transaminases.

The patient has continued on thymosin injections
20 now for 3 years with no significant or persistent side effects. Thymosin appears to have some steroid sparing effect as the prednisone dose is now stable at 7.5 mg daily.

Example 2

Patient was an 18 year old white male with a diagnosis of chronic autoimmune hepatitis and cirrhosis. This diagnosis was made by liver biopsy and
5 compatible serology (ANA of 1 to 10,000 and ASMA of 1 to 2560). His problems began 18 months prior to the diagnosis with his initial episode of jaundice. He was otherwise asymptomatic at that time, although his liver enzymes were markedly abnormal.

10 He had spontaneous remission of his jaundice and did well until approximately 12 months later when he had a recurrent episode. At that time he had associate symptoms of acholic stools and dark urine. He continued to do well until he presented with epistaxis
15 and hematochezia. Because of adenopathy, splenomegaly, and hematologic abnormalities a diagnosis of lymphoma was entertained initially. However, further evaluation including exploratory laparotomy with splenectomy and liver biopsy, as well as several blood tests, finally
20 confirmed the diagnosis of autoimmune hepatitis with cirrhosis.

Because of the patient's splenectomy, he was at an increased risk for infection. This problem could potentially be exacerbated with the use of prednisone.
25 Therefore, the patient was offered the option of $T\alpha_1$ treatment alone. He elected to pursue this option and was started on 1.6 mg $T\alpha_1$ injections twice weekly. At the time of drug initiation the ALT was 247, AST 382. These injections continued for approximately 5 weeks.
30 However, shortly after one month after commencing treatment, it was apparent that his transaminases were not responding, the ALT was 396 and AST 695. Therefore, $T\alpha_1$ was discontinued and the patient was started on prednisone. He responded to the prednisone

therapy with a substantial decrease and eventual normalization in his transaminases.

Example 3

5 Patient was a 46 year old white male with a diagnosis of chronic autoimmune hepatitis. His presenting symptoms were fatigue, myalgia and jaundice. A liver biopsy showing chronic active hepatitis with early cirrhosis and positive ANA and anti-smooth muscle antibodies confirmed the diagnosis.

10 His initial therapy consisted of imuran 50 mg/day and prednisone at 30 mg/day. This therapy was instituted at the time of diagnosis when his transaminases were approximately 10 times the upper limit of normal. The enzymes declined with this
15 therapy, however, the patient had problems with irritability and weight gain. Initial attempts at tapering the prednisone were unsuccessful. At a prednisone level of 20 mg/day his AST was elevated to 421 and his ALT remained high at 503. An increase in
20 the prednisone to 40 mg again resulted in near normalization of the transaminases and it was at this point that the patient's imuran was discontinued. However, the enzymes again became elevated and it was necessary to dose the patient with 60 mg of prednisone
25 each day. This maneuver resulted in laboratory improvement but the patient unfortunately developed steroid induced diabetes.

Because of the high doses of prednisone required to control the patient's disease process and the side
30 effects associated with these doses, the patient was offered $T\alpha_1$. The response to twice weekly 1.6 mg $T\alpha_1$ injections was favorable with a definite steroid sparing effect observed. Within 1 week the ALT decreased from 212 to 140 and the AST from 124 to 70.

We were able to decrease the prednisone to 7.5 mg every day while maintaining steady transaminase values. Unfortunately we were not able to decrease transaminases to less than 2 times the upper limit of normal. After approximately 6 weeks on prednisone at 7.5 mg/day we therefore elected to increase the patient's prednisone back to 40 mg/day. This resulted in prompt improvement of the transaminases with declining values to near normal range. After patient had maintained these normal values for approximately 8 weeks, we elected to arbitrarily stop the $T\alpha_1$ injections. Over the next 8 weeks the transaminase values again began to rise, however, with reinstitution of thymosin therapy this time we were not able to recognize a decline in the transaminase values and therefore the $T\alpha_1$ injections were discontinued. Patient was started on imuran therapy in addition to his prednisone at 60 mg/day and after several weeks on imuran we have seen near normalization of his transaminases once again.

Aside from the improvement in laboratory parameters the patient also experienced clinical benefit from the $T\alpha_1$. While taking the injections, his insulin requirements decreased and his energy level had increased and his irritability had subsided.

Example 4

Patient was a 39 year old black female with a diagnosis of chronic autoimmune hepatitis. This diagnosis was made on the basis ASMA and ANA positivity as well as a liver biopsy showing active cirrhosis. The patient's initial presentation was that of anemia and coagulopathy.

She was started on prednisone therapy with improvement in transaminase values. However she

developed an upper GI bleed secondary to duodenal ulcer and at doses of prednisone, 40 mg/day, had significant problems with irritability, restlessness and mood swings. These side effects necessitated a decrease in
5 her prednisone dose. However, at doses less than 40 mg/day, her disease activity was not controlled.

Because of the side effects of prednisone in this patient, $T\alpha_1$ therapy was offered to her as an alternative to imuran. She therefore was started on
10 1.6 mg $T\alpha_1$ injections twice weekly and on prednisone at a dose of 20 mg/day. Within 2 weeks, the ALT had decreased from 230 to 126 and the AST from 257 to 138. Over the next 4 months a slow prednisone taper to 7.5 mg/day was successful in that her transaminases
15 remained steady at about 3 times the upper limit of normal. After approximately 1 month of prednisone at 7.5 mg/day followed by 5.0 mg/day for 1 week, we saw an increase in her transaminase levels and therefore elected to increase her prednisone to 30 mg/day. This
20 resulted in prompt decrease in her transaminases to less than 2 time the upper limit of normal. Upon maintaining this normalization for 1 month, we arbitrarily elected to stop $T\alpha_1$ injections, and increase prednisone to 40 mg/day, and observe possible effect.
25 We did notice a gradual increase in the patient's transaminase values. Upon reinstituting $T\alpha_1$ therapy we failed to observe the previously identified immunosparing effect. The patient's transaminases had elevated to more than 3 times the upper limit of normal
30 and we therefore discontinued the $T\alpha_1$ and instituted imuran therapy. While on $T\alpha_1$ therapy the patient did note some clinical improvement, with lessening of her lower extremity edema, irritability and fatigue.

Examples 1, 3 and 4 show successful use of $T\alpha_1$
35 combined with prednisone in treating autoimmune

hepatitis and improving transaminases. These results also show the corticosteroid sparing effect of $T\alpha_1$.

Example 1 further illustrates a preferred embodiment of the invention, wherein $T\alpha_1$ administration
5 is commenced after transaminases have been normalized with corticosteroids and the patient's maintenance dose of corticosteroids has been determined.

In Example 2, $T\alpha_1$ was not effective as sole therapy for autoimmune hepatitis.

10 The results indicated a synergistic activity of combined treatment with $T\alpha_1$ and corticosteroid, in which the disease can be treated at reduced corticosteroid levels.

WHAT IS CLAIMED IS:

1. A method of treating autoimmune hepatitis in a patient, comprising administering to a patient in need of such treatment a drug regimen comprising an immunomodulatory amount of $T\alpha_1$ and an anti-inflammatory amount of a corticosteroid.
2. The method of claim 1 wherein said $T\alpha_1$ is administered in a dosage amount within the range of about 0.4 - 4 mg.
3. The method of claim 1 wherein said $T\alpha_1$ is administered in a dosage amount within the range of about 1 - 4 mg.
4. The method of claim 1 wherein said $T\alpha_1$ is administered in a dosage amount of about 1.6 mg.
5. The method of claim 1 wherein said $T\alpha_1$ is administered to said patient two times weekly by subcutaneous injection.
6. The method of claim 1 wherein said corticosteroid is administered in a dosage amount within the range of about 1 - 100 mg.
7. The method of claim 1 wherein said corticosteroid is administered in a dosage amount within the range of about 2 - 60 mg.
8. The method of claim 1 wherein said corticosteroid is prednisone, and said corticosteroid is administered once daily.
9. The method of claim 1 wherein said corticosteroid is prednisone, and said corticosteroid is administered on an alternating day regimen.
10. The method of claim 1 wherein said $T\alpha_1$ is administered to said patient in a T-lymphocyte-stimulating amount.
11. The method of claim 1 wherein said $T\alpha_1$ is administered to said patient in a CD4 cell-stimulating amount.

12. The method of claim 1 wherein said corticosteroid is administered to said patient in a liver necroinflammatory-inhibiting amount.

13. The method of claim 1 wherein said
5 corticosteroid is administered to said patient in a liver cirrhosis progression-inhibiting amount.

14. The method of claim 1 wherein said drug regimen is administered to said patient so as to maintain ALT levels of said patient at less than about
10 two times an upper limit of normal for said ALT levels.

15. The method of claim 14 wherein, prior to administration of said drug regimen including both said $T\alpha_1$ and said corticosteroid, a transaminase-reducing amount of said corticosteroid is administered to said
15 patient without administering $T\alpha_1$, so as to reduce serum ALT levels of the patient at less than about two times an upper limit of normal for said ALT levels.

16. The method of claim 15 wherein, during administration to said patient of the drug regimen
20 comprising $T\alpha_1$ and said corticosteroid, further including the step of reducing dosage of said corticosteroid administered to said patient, while administering both $T\alpha_1$ and said corticosteroid to said patient, and while maintaining said ALT level of said
25 patient at less than about two times an upper limit of normal for said ALT levels.

17. A pharmaceutical composition comprising separate pharmaceutical dosage units of an immunomodulatory amount of $T\alpha_1$ and an anti-inflammatory
30 amount of a corticosteroid.

18. The pharmaceutical composition of claim 17 wherein the pharmaceutical dosage unit of said $T\alpha_1$ is about 0.4 - 4 mg and the pharmaceutical dosage unit of said corticosteroid is about 1 - 100 mg.

19. The pharmaceutical composition of claim 17 wherein said corticosteroid is prednisone.

20. The pharmaceutical composition of claim 17 wherein the pharmaceutical dosage unit of $T\alpha_1$ is about 1
5 - 4 mg and the pharmaceutical dosage unit of said corticosteroid is about 2 - 60 mg.

21. The pharmaceutical composition of claim 18 wherein said pharmaceutical dosage unit of $T\alpha_1$ is about 1.6 mg.

10 22. The pharmaceutical composition of claim 18, wherein said $T\alpha_1$ is present in an injectable or infusible pharmaceutically acceptable liquid carrier.

23. The pharmaceutical composition of claim 18 wherein the pharmaceutical dosage unit of said
15 corticosteroid is orally administerable, and is present in a pharmaceutically acceptable carrier.

AMENDED CLAIMS

[received by the International Bureau on 1 March 1995 (01.03.95);
original claim 17 amended; remaining claims unchanged (1 page)]

12. The method of claim 1 wherein said corticosteroid is administered to said patient in a liver necroinflammatory-inhibiting amount.

13. The method of claim 1 wherein said
5 corticosteroid is administered to said patient in a liver cirrhosis progression-inhibiting amount.

14. The method of claim 1 wherein said drug regimen is administered to said patient so as to maintain ALT levels of said patient at less than about two times
10 an upper limit of normal for said ALT levels.

15. The method of claim 14 wherein, prior to administration of said drug regimen including both said $T\alpha_1$ and said corticosteroid, a transaminase-reducing amount of said corticosteroid is administered to said
15 patient without administering $T\alpha_1$, so as to reduce serum ALT levels of the patient at less than about two times an upper limit of normal for said ALT levels.

16. The method of claim 15 wherein, during administration to said patient of the drug regimen
20 comprising $T\alpha_1$ and said corticosteroid, further including the step of reducing dosage of said corticosteroid administered to said patient, while administering both $T\alpha_1$ and said corticosteroid to said patient, and while maintaining said ALT level of said patient at less than
25 about two times an upper limit of normal for said ALT levels.

17. A pharmaceutical composition for use in treating autoimmune hepatitis, comprising separate pharmaceutical dosage units of an immunomodulatory amount
30 of $T\alpha_1$ and an anti-inflammatory amount of a corticosteroid.

18. The pharmaceutical composition of claim 17 wherein the pharmaceutical dosage unit of said $T\alpha_1$ is about 0.4 - 4 mg and the pharmaceutical dosage unit of said corticosteroid is about 1 - 100 mg.

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/US 94/12106

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/22 //(A61K38/22,31:57)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	J. MED. VIROL. (USA), 1987, VOL. 21, NO. 1, PAGE(S) 25-37, Eichberg J.W. et al 'Effect of thymosin immunostimulation with and without corticosteroid immunosuppression on chimpanzee hepatitis B carriers' see abstract	17
A	WO,A,93 05806 (ALPHA 1 BIOMEDICALS, INC.) 1 April 1993 see abstract	1-23

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

7 February 1995

Date of mailing of the international search report

16.02.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 94/ 12106

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
REMARK: Although claims 1-16 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1-16
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Intern. Appl. Application No

PCT/US 94/12106

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9305806	01-04-93	AU-A- 2644792	27-04-93
		EP-A- 0603305	29-06-94
		FI-A- 941133	10-03-94
		JP-T- 6510998	08-12-94
		NO-A- 941310	12-04-94
